Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder : AAA randomized, double-blind, placebo-controlled study in stimulant-n̈aive Swedish children and adolescents

European Child and Adolescent Psychiatry

Volumn 18, Issue 4, 2009, Pages 240-249

  Svanborg, Pär ^a,b   Thernlund, Gunilla ^c   Gustafsson, Per A ^d   Hägglöf, Bruno ^e   Poole, Lynne ^f   Kadesjö, Björn ^g  

^a Box 721   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ADHD; Atomoxetine; Clinical research trial; Parenting education; Pharmacotherapy

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PSYCHOEDUCATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SWEDEN; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL HEALTH; PATIENT EDUCATION AS TOPIC; PROPYLAMINES; QUALITY OF LIFE; QUESTIONNAIRES; SWEDEN;

EID: 62549108162     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-008-0725-5     Document Type: Article

References (38)

1. American 2000 Diagnostic and statistical manual of mental disorders DSM
2. H Remschmidt Global ADHD Working Group 2005 Global consensus on ADHD/HKD Eur Child Adolesc Psychiatry 14 3 127 137
3. J Biederman SV Faraone S Milberger J Guite E Mick L Chen D Mennin A Marrs C Ouellette P Moore T Spencer D Norman T Wilens I Kraus J Perrin 1996 A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders Arch Gen Psychiatry 53 437 446
4. C Gillberg B Kadesjo 2003 Why bother about clumsiness? The implications of having developmental coordination disorder (DCD) Neural Plast 10 1-2 59 68
5. LS Goldman M Genel RJ Bezman PJ Stanetz 1998 Diagnosis and treatment of attention-deficit/hyperactivity disorders in children and adolescents JAMA 279 1100 1107
6. J Biederman MC Monuteaux E Mick T Spencer TE Wilens JM Silva LE Snyder SV Faraone 2006 Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study Psychol Med 36 2 167 179
7. J Biederman SV Faraone 2005 Attention-deficit/hyperactivity disorder Lancet 366 237 248
8. R Escobar CA Soutullo A Hervas X Gastaminza P Polavieja I Gilaberte 2005 Worse quality of life for children with newly diagnosed attention-deficit/ hyperactivity disorder, compared with asthmatic and healthy children Pediatrics 116 364 369
9. Bernet W, Dulcan MK, Greenhill LL, Pliszka SR (2004) AACAP-endorsed managing: attention-deficit/hyperactivity disorder. Guidelines (pocketcard) version 2.0 American academy of child and adolescent psychiatry. International guidelines center. Available at: http://www.myguidelinescenter.com
10. UK Strattera SPC (2007)
11. D Kelsey C Sumner C Casat DL Coury H Quintana KE Saylor VK Sutton J Gonzales SK Malcolm KJ Schuh AJ Allen 2004 Once-daily atomoxetine treatment for children with attention-deficit hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial Pediatrics 114 1 e1 e8
12. D Michelson AJ Allen J Busner C Casat D Dunn C Kratochvil J Newcorn FR Sallee RB Sangal K Saylor S West D Kelsey J Wenicke NJ Trapp D Harder 2002 Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 159 1896 1901
13. D Michelson Faires De J Wenicke DK Kelsey KL Kendrick FR Sallee T Spencer Atomoxetine ADHD Study Group 2001 Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled dose-response study Pediatrics 108 e83
14. T Spencer JH Heiligenstein J Biederman DE Faries CJ Kratochvil CK Conners WZ Potter 2002 Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder J Clin Psychiatry 63 1140 1147
15. M Weiss R Tannock C Kratochvil D Dunn J Velez-Borras C Thomason R Tamura D Kelsey L Stevens AJ Allen 2005 A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD J Am Acad Child Adolesc Psychiatry 44 7 647 655
16. Mosholder AD (2006) Psychiatric adverse advents in attention-deficit/ hyperactivity disorder (ADHD) clinical trials. Food and Drug Administration, Pediatric Advisory Committee, 22 March, 2006. Available at: http://www.fda.gov/ ohrms/dockets/AC/06/slides/2006-4210s-14-Mosholder-PsychiatricAdverse Events-files/frame.htm
17. AW Riley CB Forrest B Starfield GW Rebok JA Robertson BF Green 2004 The parent report form of the CHIP-child edition: reliability and validity Med Care 42 3 210 220
18. RileyAW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G (2006) Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-child edition. Eur Child Adolesc Psych 15(Suppl 1):1/63-1/71. doi: 10.1007/ s00787-006-1009-6
19. MD Weiss A Virani M Wasdell M Faulkner K Rea RD Freeman G Weiss V Jokhani 2006 Atomoxetine in clinical practice Future Neurol 1 3 249 258
20. J Kaufman B Birmaher D Brent U Rao C Flynn P Moreci D Williamson N Ryan 1997 Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data J Am Acad Child Adolesc Psychiatry 36 7 980 989
21. DuPaul GJ, Power TJ, Anastopoloulos AD, Reid R (1998) ADHD rating scale-IV checklist, norms and clinical interpretation. The Guilford Press, New York
22. DE Faries I Yalcin D Harder JH Heiligenstein 2001 Validation of the ADHD rating scale as a clinician administered and scored instrument J Atten Disord 5 39 47
23. Guy W (1976) ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health (NIMH), Psychopharmacology Research Branch (revised 1976)
24. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen H-C, Sonuga-Barke EJS, Taylor E (2006) Long-acting medication for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry. doi: 10.1007/s00787-006-0549-0
25. Sutton VK, Milton DR, Ruff DD, Allen AJ (2004) Atomoxetine's efficacy over time in children and adolescents with attention-deficit/hyperactivity disorder. In: Poster presented at AACAP, Washington, 19-24 October, 2004
26. Newcorn JH, Kratochvil CJ, Allen AJ, Milton DR, Moore R, Michelson D (2005) Atomoxetine and OROS methylphenidate for the treatment of ADHD: acute results and methodological issues. In: Poster presented at NCDEU
27. S van der Oord PJM Prins J Oosterlaan PMG Emmelkamp 2007 Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD? Eur Child Adolesc Psychiatry 16 48 57
28. MTA Cooperative Group 1999 Moderators and mediators of treatment reponse for children with attention-deficit/hyperactivity disorder Arch Gen Psych 56 1088 1096
29. MTA Cooperative Group 1999 A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder Arch Gen Psych 56 1073 1086
30. L McLeary T Ridley 1999 Parenting adolescents with ADHD: evaluation of a psychoeducation group Parent Education Councelling 38 3 10
31. VJ Monastra 2005 Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuron-educational approach Int J Psychophysiol 58 71 80
32. PS Jensen D Martin DP Cantwell 1997 Comorbidity in ADHD: implications for research, practice, and DSM-V J Am Child Adolesc Psychiatry 36 1065 1079
33. GJ August GM Realmuto AW MacDonald 3rd SM Nurent R Crosby 1996 Prevalence of ADHD and comorbid disorder among elementary children screened for disruptive behavior J Abnorm Child Psychol 24 571 595
34. JK Buitelaar J Barton M Danckaerts E Friedrichs C Gillberg PL Hazell H Hellemans M Johnson LJ Kalverdijk G Masi D Michelson O Revol JS Sebastian S Zhang A Zuddas 2006 A comparison of North American versus non-North American ADHD study populations Eur Child Adolesc Psychiatry 15 177 181
35. RW Greene J Biederman S Zerwas MC Monuteaux JC Goring SV Faraone 2002 Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder Am J Psychol 159 1214 1224
36. M Kuhne R Schachar R Tannock 1997 Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivitiy disorder J Am Acad Child Adolesc Psychiatry 36 1715 1725
37. JH Newcorn TJ Spencer J Biederman DR Milton D Michelson 2005 Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder J Am Acad Child Adolesc Psychiatry 44 3240 3248
38. D Geller C Donnelly F Lopez R Rubin J Newcorn V Sutton R Bakken M Paczkowski D Kelsey C Sumner 2007 Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder J Am Acad Child Adolesc Psychiatry 46 9 1119 1127